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Abstract
Background: The aim was to assess the outcome of a total pancreatectomy (TP).
Methods: From 1993 to 2010, 56 patients underwent an elective TP for intraductal papillary mucinous
neoplasia (n = 42), endocrine tumours (n = 6), adenocarcinoma (n = 5), metastases (n = 2) and chronic
pancreatitis (n = 1). Morbidity and survival were analysed. Long-term survivors were assessed prospec-
tively using quality-of-life (QoL) questionnaires.
Results: Five patients developed gastric venous congestion intra-operatively. Post-operative morbidity
and mortality rates were 45% and 3.6%, respectively. An anastomotic ulcer occurred in seven patients,
but none after proton pump inhibitor therapy. There were five inappropriate TPs according to definitive
pathological examination. Overall 3- and 5-year survival rates were 62% and 55% respectively; five
deaths were related to TP (two postoperative deaths, one hypoglycaemia, one ketoacidosis and one
anastomotic ulcer). Prospective evaluation of 25 patients found that 14 had been readmitted for diabetes
and that all had hypoglycaemia within the past month. The glycated haemoglobin (HbA1c) was 7.8%
(6.3–10.3). Fifteen patients experienced weight loss. The QLQ-C30 questionnaire showed a decrease in
QoL predominantly because of fatigue and diarrhoea, and the QLQ-PAN26 showed an impact on bowel
habit, flatulence and eating-related items.
Discussion: Morbidity and mortality rates of TP are acceptable, although diabetes- and TP-related
mortality still occurs. Endocrine and exocrine insufficiency impacts on the long-term quality of life.
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Introduction
The first successful total pancreatectomies (TPs) were performed
in the early 1940s in the USA.1 Enthusiasm for TP soon emerged,
and some centres recommended TP in the treatment of pancreas
carcinoma2 to improve long-term survival. Indeed, some surgeons
considered that the high recurrence rate of a pancreatic carcinoma
after a partial pancreatectomy could be explained in part by
the high prevalence of a tumor3 multicentricity requiring total
excision of the gland. Moreover, the absence of pancreatic anas-
tomosis was considered as a means to reduce post-operative mor-
bidity related to pancreatic fistulae. However, in studies published
in the 1990s, TP has long been associated with unfavourable
prejudice with a high peri-operative mortality rate4–6 and no clear
benefit of survival.5,6
Nowadays, diffuse pancreatic disease represents the main indi-
cations for TP:7 intraductal papillary mucinous neoplasm
(IPMN),8,9 end-stage chronic pancreatitis,10–12 neuroendocrine
tumours, especially in the setting of multiple endocrine neoplasia
orVonHippel–Lindau disease8,13,14 andmore rarelymultiplemeta-
static lesions (mainly from renal cancer).13,14 The management of
pancreatic insufficiency has improved over time and TP is now an
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option that should be considered to treat selected pancreatic
diseases.
A few previous studies focused on long-term follow-up and
quality of life (QoL) after TP13–15 and concluded that TP is now a
viable option with an acceptable QoL. These results should be
interpreted in the light of the type of QoL scale used and the
indications for surgery. Recent data on technical complications
and late pancreatic endocrine and exocrine insufficiency are also
lacking therefore the current study was undertaken to evaluate
these outcomes in a high-volume centre.
Patients and methods
Patient characteristics
Data of patients undergoing a TP between October 1993 and
December 2010 in the department of HPB Surgery, Beaujon
Hospital/University Paris VII, France, were collected retrospec-
tively from clinical files. All patients with an elective TP (either
one-step TP or completion pancreatectomy after a previous
partial resection) were included. Patients who underwent salvage
TP (because of severe pancreatic leakage after a first pancreatic
resection) were excluded because of the high mortality and mor-
bidity rates associated with this procedure and the potential to
impact on the long-term QoL.12,13
Demographic data, indications for TP, peri-operative data
(such as surgical technique, hospital mortality, morbidity and
reoperation) and pathological examination results were recorded.
A ‘pre-operative diagnosis’ was established according to imaging
findings using thin slice contrast-enhanced spiral CT, completed
by MRI or endoscopic ultrasound when appropriate. Fine-needle
aspiration was not performed for cytological/histological diagno-
sis after 2003 as a result of disappointing results using this
technique.16
TP technique
All TPs were performed as open procedures by two senior sur-
geons (A.S. and S.D.). The following parameters were collected:
completion of a previous pancreatic resection, extension of a pan-
createctomy for positive frozen section of the pancreatic margin,
venous resection, extension of resection to adjacent organs,
splenectomy and pylorus preservation. The spleen and pylorus
were usually preserved when an invasive tumour was deemed
localized far from these structures (i.e. in the pancreatic head and
in the distal pancreas, for spleen and pylorus preservation, respec-
tively). In patients primarily operated on for IPMN, a pancreate-
ctomy was extended up to TP if a frozen section revealed at least:
(i) IPMN adenoma on the main duct, or (ii) at least borderline
IPMN (moderate dysplasia) on branch ducts, or (iii) invasive
carcinoma.17 During pancreaticoduodenectomy, resection was
extended to the left, preserving the splenic vessels, with additional
pancreatic division and frozen section every 3 cm. During a distal
pancreatectomy, an additional pancreatectomy was done by resec-
tion of the head/neck junction on the left side of the common bile
duct and, if a frozen section revealed persistent IPMN lesions, by
completion pancreatectomy.
Early post-operative medical management
After their discharge, patients were referred to an endocrinology
department for the management of post-operative diabetes. Exo-
crine insufficiency was managed by oral pancreatic enzymes
(25 000 units/tablet) three times a day during the main meals.
Patients were aware of the need to adapt the number of pancreatic
enzymes tablets/capsules to their fat intake, and to open the cap-
sules or take granules if needed.
Follow-up
Most recent follow-up data were collected from clinical hospital
files and/or telephone interviews with the patients’ general prac-
titioner, gastroenterologist or endocrinologist. All patients were
periodically followed by an endocrinologist or gastroenterologist
although this was normally undertaken locally. Living patients
were asked to participate in long-term assessment, including
blood tests and three questionnaires. Blood tests included glycated
haemoglobin (HbA1c), liver function tests (LFTs), prothrombin
time, creatinine, albumin, pre-albumin and orosomucoid. The last
three tests were expressed as percentages of normal values accord-
ing to gender and age as displayed by the assay office. Question-
naires included an institutional standardized questionnaire as well
as two QoL questionnaires: the EORTC QLQ-C30 (version 3.0,
French neutral) and the EORTC QLQ-PAN26 (French).
Questionnaires
The institutional standardized questionnaire collected informa-
tion about sociodemographic data, exocrine function and endo-
crine function.
The European Organisation for Research and Treatment of
Cancer ‘EORTC-QLQ-C30’18 is a questionnaire developed to
assess the QoL of cancer patients. It includes multi- and single-
item measures, including functional and symptom scales and
global health status. A linear transformation was used to stand-
ardize the raw score, producing a score ranging from 0 to 100.
Themodule ‘EORTC-QLQ-PAN26’19 is specifically intended for
pancreatic cancer patients at all disease stages, in order to measure
health status and disease burden. The same linear transformation
was used to standardize the raw score. Items regarding hepatic
failure (nos 41 and 42) and ascites (no. 32) were deleted because of
an absence of patients with ongoing liver metastases. Items
regarding the side effects (nos 38, 43, 50) were deleted because of
the absence of current treatment at the time of assessment. Items
regarding sexuality (nos 55 and 56) were deleted because of the
few percentage of answers.
Ethics
The design of the study was approved on 20 May 2011 by our
institutional review board under the registration number
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IRB00006477 (Comité d’évaluation de l’éthique des projets de
recherche biomédicale CEERB du GHU Nord). Patients who
accepted the long-term follow-up (including institutional ques-
tionnaire, blood tests and QoL tests) all signed an informed
consent.
Statistical analysis
Graph Pad Prism 5.0 software for Mac OS X (GraphPad Software,
Inc., La Jolla, CA, USA) was used for statistical analysis. Qualita-
tive data are expressed as absolute numbers and percentages, and
quantitative data are expressed as median and range in square
brackets. Comparisons of groups of patients were performed
using the Mann–Whitney test and Fisher’s exact test. Graphs of
QoL parameters from QLQ-C30 and QLQ-PAN26 questionnaires
are represented with bars for the mean and error bars for the
standard error of the mean. Survival was estimated using the
Kaplan–Meier method. Patients alive at the last follow-up or who
were lost to follow-up were censored.
Results
Fifty-six patients undergoing an elective TP between 1993 and
2010 were identified. Forty-eight per cent of the patients (n = 27)
were male, and the median age at the time of TP was 59 years
[27–81].
Pre-operative data
A pre-operative diagnosis included non-invasive IPMN (n = 20,
36%), invasive IPMN (n = 22, 39%), neuroendocrine tumours
(n = 6, 11%; including four associated with multiple endocrine
neoplasia and one with nesidioblastosis), ductal adenocarcinoma
without IPMN (n = 4, 7%), metastasis from renal carcinoma (n =
2), acinar cell carcinoma (n = 1) and familial chronic pancreatitis
with intractable pain (n = 1).
In 39 of the 56 cases (70%), a TP was performed in one step,
including 29 patients with a pre-operative indication of TP, and
10 patients with an intra-operative indication based on frozen
section results. In 29% of the 56 cases (n = 16), a ‘completion
pancreatectomy’ was performed after a previous pancreatic resec-
tion. The remaining patient had a three-step TP. For patients with
a 2- (n = 16) or 3-step TP (n = 1), a previous resection was
a pancreaticoduodenectomy (n = 7), distal pancreatectomy
splenectomy (n = 7), central pancreatectomy (n = 2) and enuclea-
tion (n = 2). Eight of them had an invasive neoplasm (IPMN: n =
5, metastases from renal carcinoma: n = 2, endocrine carcinoma:
n = 1) on the 1st-step specimen, and the median time elapsed
between the two operations was 43 months [0.2–81].
Intra-operative data
Pylorus preservation was performed in 57% of patients (n = 32)
and the spleen was preserved in 20% of patients (n = 11).A venous
resection was performed in 11% (n = 6).
Intra-operative gastric venous congestion was observed in five
patients (9%): (i) transient, after resection of splenic and left
gastric veins (n = 1), (ii) permanent, requiring a subtotal gastrec-
tomy (n = 1) or appropriate venous reconstructions (n = 3) of the
splenic vein (n = 1), of the left gastric vein (n = 1), and of both the
left and right gastric veins (n = 1).
Post-operative course
The overall morbidity rate was 45% (n = 25 patients) with an 8.9%
relaparotomy rate (n = 5 patients). Details are given in Table 1.
Two patients (3.6%) died post-operatively: one 72-year old female
patient was re-operated on for a biliary fistula and died of septic
shock 2 days after re-intervention, and one 81-year old woman
died from acute respiratory distress syndrome and multiple organ
failure at postoperative day 52.
Comparison of the two patient cohorts was undertaken: the
first 28 patients, operated on from 1993 to 2005, and the last 28
patients, from 2006 to 2010. The two post-operative deaths were
observed during the second period of time. The overall morbidity
rate was similar in both groups: 12/28 in the first period and 13/28
Table 1 Post-operative complications in 56 patients undergoing a total pancreatectomy (TP)
Type of complication Nb (%) Treatment
Medical/conservative Re-intervention
Delayed gastric emptying 9 (16%) 9 –
Sepsis/angiocholitis 5 (9%) 5 –
Intra-abdominal abscess 3 (5%) 3 –
Early anastomotic ulcer 2 (4%) – 2a
Biliary fistula 2 (4%) – 2
Haemorrhage 2 (4%) 1 gastrointestinal haemorrhage 1 intraabdominal bleeding
Pneumonia 2 (4%) 2 –
Occlusion 1 (2%) – 1
Splenic infarction 1 (2%) 1 –
Wound abscess 1 (2%) 1 (bed-side drainage) –
aOne patient was re-operated on for both an early anastomotic ulcer and a biliary fistula.
884 HPB
HPB 2013, 15, 882–892 © 2013 International Hepato-Pancreato-Biliary Association
in the second period (P = 1.000), and did not differ according to
the surgeon who performed the TP. Pylorus preservation was less
frequently used in the first period (12/28 versus 20/28 in the
second one, P = 0.057) and delayed gastric emptying was more
frequently observed in the first period (8/28 versus 1/28 in the
second, P = 0.025). However, a comparison of patients with
pylorus preservation versus patients who had an antrectomy did
not reveal any significant difference with regards to delayed gastric
emptying (3/32 versus 6/24, respectively; P = 0.151).
Pathological examination
Of the 20 non-invasive diffuse IPMN diagnosed pre-operatively, 9
were confirmed by pathologic examination (Fig. 1), 6 were inva-
sive at definitive pathological examination, 2 were non-invasive
but localized at definitive pathological examination and 3 were
‘false’ IPMN (lupus pancreatitis n = 1, polycystic disease n = 1,
obstructive pancreatitis owing to anastomotic stenosis after pan-
creatoduodenectomy for IPMN n = 1). Overall, according to the
specimen definitive pathological examination, five inappropriate
TPs (9%) have been performed (two localized IPMN and three
‘false’ IPMN).
Long-term follow-up
The median follow-up of patients (except the two patients who
died post-operatively) was 35 months [4–168], with one patient
lost to follow-up after 18 months. Six patients (11%) were read-
mitted once for a hypoglycaemia coma and five patients (9%)
presented with anastomotic ulcers, including two patients requir-
ing re-operation.
Overall, seven patients (13%) experienced anastomotic ulcers:
two in the early post-operative course and five during follow-up.
All of these seven patients underwent a TP in the first period
between 1993 and 2005 (P = 0.010 versus the second period) when
permanent proton pump inhibitors (PPI) were not given rou-
tinely. No anastomotic ulcer was observed in the second period,
after routine permanent PPI administration. Five out of 24
patients who had an antrectomy developed an anastomotic ulcer
compared with two out of 32 patients with pylorus preservation
(P = 0.114).
At the census date, the overall mortality rate was 47% (26/56
patients) with 20 deaths attributable to the underlying pancreatic
disease, one to an endocarditis and five directly as a consequences
of TP. The causes of death related to TP included: two early post-
operative deaths (as described above), one perforated anastomotic
ulcer, one hypoglycaemia and one ketoacidosis.
Overall, the median 3- and 5-year survivals for all patients (n =
56) were respectively 122 months, 62% and 55% (Fig. 2). For
patients with IPMN (Fig. 3), the median, 3- and 5-year survivals
were, respectively, 156 months, 90% and 90% for non-invasive
IPMN, 20 months, 40% and 22% for invasive IPMN, and 46
months, 55% and 43% for all IPMN. Among the 15 patients with
invasive IPMN who deceased from disease recurrence, 20% of
them had an isolated regional recurrence and 80% presented
metastatic lesions at time of recurrence. The three patients with
‘false’ IPMN are alive, including one who was re-operated for an
anastomotic ulcer. Of the six patients with an endocrine tumour,
two developed metastases: one patient died at 79 months and the
other is currently awaiting a liver transplantation. Of the five
patients with acinar cell carcinoma or adenocarcinoma without
IPMN, four died: three from recurrence and one from ketoacido-
sis 5 months after surgery. Their median survival was 71 months
Invasive IPMN:
n = 6
Localized
non-invasive
IPMN:
n = 2
«False» IPMN:
n = 3
«True» non-invasive
diffuse IPMN:
n = 9
Figure 1 Definitive results of pathological examination of in the 20
patients undergoing a total pancreatectomy (TP) with the pre-
operative diagnosis of non-invasive diffuse Intraductal papillary
mucinous neoplasm (IPMN)
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[5–122]. The three remaining patients who underwent TP for
renal cancer metastases and chronic pancreatitis are still living and
are in a good general condition, with a follow-up of 32 and 7
months and 22 months, respectively.
Long-term prospective evaluation and
QoL questionnaires
Among the 30 survivors, 25 agreed to participate prospectively in
the study. Two declined to participate, one had severe comorbidity
(renal cancer, renal failure and antiphospholipid antibody syn-
drome) affecting the QoL and was considered unsuitable for
evaluation, one was lost to follow-up after a 18-month follow-up
and one patient was living abroad and not contactable at the time
of inclusion. The long-term assessment took place 66 months
[7–168] after TP or completion of a pancreatectomy. Eleven
patients (44%) were male and with a median age was 64 years
[33–79]. Eighteen patients (72%) did not receive a higher educa-
tion (college or university). Indications for TP were: non-invasive
IPMN (n = 7), ‘false’ IPMN (n = 2), invasive IPMN (n = 8),
endocrine tumour (n = 4), ductal adenocarcinoma (n = 1), metas-
tases from renal cancer (n = 2) and chronic pancreatitis (n = 1).No
patients are currently undergoing treatment for recurrence.
Exocrine function
Since a TP, 15 patients lost weight, with a median of 9 kg [2–14]
and their weight at the time of analysis was 85% [78–97] of their
pre-operative weight. Four patients gained weight (12.5 kg
[4–22]). The 25 patients had 2 [1–5] stools per day, which were
liquid in one-quarter of the patients. Seven patients had night
stools, and for five patients diarrhoea stools were a limiting factor
in everyday life. The median daily intake of pancreatic enzymes
supplements was 6 [3–18] capsules (25 000 units per capsule) and
5 patients took other medications for intestinal transit, including
loperamide (n = 1) and diosmectite (n = 1).
LFTs and prothrombin time were within normal ranges; par-
ticularly no cholestasis was noticed (data not shown). The renal
function was usually preserved with a median serum creatinine of
82 mmol/l [50–163]. Nutrition markers included albumin of
100% [81–100], pre-albumin 100% [70–100] and orosomucoid
100% [63–100] of normal values.
Endocrine function
Patients assessed their glycaemia 5 times per day [3–10] and
required 16 units [7–48] of long-acting insulin and 21 units
[7–70] of rapid-acting insulin. One patient had an insulin pump.
During the past month, they all had experienced hypoglycaemia
(glycaemia<0.40 g/l) with a median of 10 times [1–36]. Fourteen
patients have been readmitted since TP for diabetes equilibration,
mostly (n = 8) for hypoglycaemic episodes. Ten patients had
already had loss of consciousness due to hypoglycaemia. The
median glycated haemoglobin was 7.8 [6.3–10.3] with no differ-
ence between non-malignant and malignant aetiologies (P =
0.550). Nine patients had a glycated haemoglobin level above 8%.
QoL questionnaires: EORTC-QLQ-C30 and QLQ-PAN 26
In the QLQ-C30 (Fig. 4), the global health status was scored 75%
[17–100]. Functional scales scores had medians ranging from 83
to 100%, representing a high QoL in physical, role, emotional,
cognitive and social functioning. Regarding symptom scales,
scores were relatively low (corresponding to a high QoL) except
for fatigue (median of 33%) and diarrhoea (33%).
P
er
 c
en
t s
ur
vi
va
l
Non-invasive IPMN (n = 11)
All IPMN (n = 39)
Invasive IPMN (n = 28)
0
0
20
40
60
80
100
12 24 36 48 60 72 84
Number of subjects at risk
Non-invasive IPMN 11 11 11 10 8 6 4 4
Invasive IPMN 28 21 12 8 6 4 4 3
All IPMN 39 32 22 16 13 9 7 6
Figure 3 Survival of intraductal papillary mucinous neoplasm (IPMN)
patients
QLQ-C30%
100
80
60
40
20
Gl
ob
al 
he
alt
h 
sta
tu
s
Ph
ys
ica
l fu
nc
tio
nin
g
Ro
le 
fu
nc
tio
nin
g
Em
ot
ion
al 
fu
nc
tio
nin
g
Co
gn
itiv
e 
fu
nc
tio
nin
g
So
cia
l fu
nc
tio
nin
g
Fa
tig
ue
Na
us
ea
 &
 Vo
m
itin
g
Pa
in
Dy
sp
ne
a
In
so
m
nia
Ap
pe
tite
 lo
ss
Co
ns
tip
at
ion
Di
ar
rh
oe
a
Fin
an
cia
l d
iffi
cu
ltie
s
0
Figure 4 Results of QLQ-C30 quality-of-life (QoL) questionnaires
QLQ-C30: a higher score represents better QoL for global health and
functional scales (striped plots) and worse QoL for symptoms scales
(white plots). Plots display the mean and error bars the standard
deviation of the mean
886 HPB
HPB 2013, 15, 882–892 © 2013 International Hepato-Pancreato-Biliary Association
In the QLQ-PAN26 score (Fig. 5), the most affected symptoms
were altered bowel habits, flatulence and eating-related items.
Patients were not highly satisfied with health care (information
and support) with a median of 31%.
Scores of global health status (QLQ-C30) and of health care
satisfaction (QLQ-PAN26) were not affected by gender (P = 0.229
and P = 0.211, respectively), age below or above 60 years at the
time of TP (P = 0.373 and P = 0.587, respectively) and a higher
education level (P = 0.380 and P = 0.762, respectively).
Discussion
This study indicates that TP is a reasonable option in some diffuse
pancreatic diseases, mainly IPMN, as operative mortality is low
and long-term consequences of TP are now better managed, with
an acceptable morbidity and QoL. Indications for TP should be
carefully selected as the best long-term survival is observed for
non-invasive IPMN whereas survival after TP for invasive IPMN
or adenocarcinoma remains disappointing. TP can result in severe
gastric congestion requiring some specific technical features, and
the risk of an anastomotic ulcer can be prevented by routine
permanent administration of PPI. However, TP should not be
considered as a common procedure as diabetes management
remains a challenge and exocrine insufficiency impacts on every-
day life.
After the first enthusiasm for TP, results of large series of TP for
pancreatic adenocarcinoma were published in the late 1980s and
1990s. They showed a high peri-operative mortality rate (13% in
that of Launois et al.’s,4 17% in Baumel et al.’s5 and up to 27% in
Ihse et al.’s series6) with no clear survival benefit on median sur-
vival (7 to 12 months).5,6 Furthermore, the frequency of tumour
multicentricity of pancreatic carcinoma was then revised down-
ward, as low as 6%.20 With the improving management of pancre-
atic fistulae, situations where a TP was performed in patients with
a pancreatic remnant considered unsuitable for anastomosis had
become exceptional. Nowadays, the role of TP in the management
of pancreatic adenocarcinoma remains limited to an isolated posi-
tive neck margin,21 familial pancreatic cancer or underlying pan-
creatic disease such as IPMN.22 The long-term survival of patients
with TP for adenocarcinoma seems to be similar to those of
patients receiving pancreatoduodenectomy, as demonstrated in
2009 in the Surveillance, Epidemiology and End Results (SEER)
database in the USA.23 As for an extended lymphadenectomy and
increased soft tissue clearance, extension of a pancreatectomy does
not improve survival24,25 comparatively to a pancreaticoduodenec-
tomy and, therefore, should not ‘justify’ routine TP.
Regarding indications of TP, this series indicates that IPMN is
currently the most frequent indication with good overall long-
term results. In other series, 3-year survival rates range from 88%13
to 95%26 for non-invasive IPMN, and decreases to 45%8 to 49%26
in case of invasive component. This difference in the survival rate
between invasive and non-invasive IPMN underlines the need to
determine accurately the clinical and morphological features of
invasive IPMN. When invasive IPMN is strongly suspected pre-
operatively, the poor life expectancy and the long-term conse-
quences of TP including decreased QoL should be taken into
account. In this setting, a partial pancreatectomy, leaving a pan-
creatic remnant harbouring non-invasive lesions, could be an
alternative to TP.27 Conversely, in patients with non-invasive
IPMN, obtaining tumour-free margins probably allows a decrease
in the rate of intra-pancreatic recurrence,28 as these patients have
a long-life expectancy (Fig. 3). As a pre-operative diagnosis of
invasive malignancy is still not reliable, as demonstrated in our
series, an intra-operative frozen section could be performed not
only on the pancreatic margin but also on the specimen to detect
an invasive component. Thus, results of a frozen section could
help the surgeon to more precisely decide if completion of a
pancreatectomy is indicated.
Our study also suggests that, in patients with suspected diffuse
IPMN, indications should be driven by histology as misdiagnoses
can occur. In the present series, five TPs were inappropriately
performed according to imaging findings mimicking diffuse
IPMN. As a matter of fact, the diagnosis of IPMN is usually not
supported pre-operatively by cytological or histological studies.16
As symptoms of IPMN are not specific, we now recommend per-
forming a TP only after confirmation of both diagnosis of IPMN
and extension into the whole gland, using intra-operative frozen
sections with an accuracy of up to 94%.16 The pancreatic segments
harbouring the most severe lesions should be identified by pre-
operative workup and resected at first. The pancreatic remnant
should then be resected only in case of worrisome findings on the
pancreatic cut surface at frozen section examination.
Intra-operatively, we observed gastric venous congestion in five
patients, requiring a subtotal gastrectomy or adequate venous
reconstruction. Indeed, TP with an antrectomy and splenectomy
leaves the stomach only vascularized by the left gastric vessels. The
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left gastric vein is sometimes difficult to preserve due to anatomi-
cal variations, inflammatory changes or tumour involvement.29 To
our knowledge, the risk of gastric venous congestion during TP
has not been precisely assessed, but only mentioned in one Japa-
nese study.30 Indeed, gastric venous congestion may resolve spon-
taneously in some cases, as it occurred in one of our patient, so
venous reconstruction might not be necessary in all patients. We
believe that pylorus preservation combined with preservation of
right gastric vessels can maintain venous drainage and should be
considered in all patients undergoing TP or a partial pancreatec-
tomy with a possible further pancreatic resection (mainly IPMN
patients). Another important drawback of TP is the risk of an
anastomotic ulcer, which can occur both in the early post-
operative course and in the long term, as demonstrated in our
series. This complication can be severe, resulting in reoperation or
even death. The risk of an anastomotic ulcer after TP has been
suggested since the 1980s31,32 and persisted in more recent series.33
We observed a anastomotic ulcer with or without pylorus preser-
vation so this complication could not be prevented technically.
However, we observed no anastomotic ulcer after routine admin-
istration of PPI hence we strongly recommend life-long treatment
with PPI for all TP patients.
Pancreatic diabetes mellitus has for main characteristics a
complete lack of endogenous insulin and glucagon, leading to
frequent and deep states of hypoglycaemia with hyperglycaemic
episodes that can be difficult to control (brittle diabetes34). In this
study, 40% of our patients already had a loss of consciousness
owing to hypoglycaemia, and a median of 10 hypoglycaemic epi-
sodes per month for all patients, which is consistent with previ-
ous studies.8 More than half of our patients were readmitted
for diabetes equilibration, which is higher than previously
described.13,35 We observed a glycated haemoglobin rate of 7.8%,
also consistent with the literature, which reported rates ranging
from 6.7% in benign disease13 to 9%.8 However, we did not find
any difference between malignant and non-malignant disease, as
observed by Muller et al.13 The severity of TP-induced diabetes
justifies reinforcing patient education. We now do this routinely
by referring the patient to a department of endocrinology
directly from our surgical department once early post-operative
surgical problems have been resolved. In this way, we aim to rein-
force patients’ information that has been scored unfavourably in
the QLQ-PAN26. The patients’ socio-economic level also should
be taken into account to adapt their education for adequate dia-
betes management. However, we did not observe any difference
with regards to long-term quality of life according to patients’
age, gender or education level, suggesting that the determination
of patients who will be able to manage pancreatic diabetes
remains challenging.
In this series, the early post-operative mortality rate was 3.6%,
which is in accordance with other published studies, from 2%26
to 8%36 (Table 2). Our data suggest that reported mortality of
TP should also include long-term deaths from TP-related com-
plications. This result is in accordance with some others
series, which reported some deaths from hypoglycaemia during
follow-up.15
Although 68% of patients in the present study lost weight,
which is within previously reported ranges13,35 (Table 3), evalua-
tion of nutrition markers showed that no patient was suffering
from malnutrition. In 1991, Dresler et al.34 first described the
metabolic consequences of TP, in 45 patients who underwent TP
from 1978 to 1988. They reported significant chronic diarrhoea in
10% of patients, with abnormal low levels of fat-soluble vitamins,
magnesium and trace elements in individual patients in spite of a
well-conductedmultivitamin supplementation. In the same study,
liver function tests (LFTs) showed elevated levels of serum
transaminases (ASAT and ALAT), as well as alkaline phosphatase
in almost all patients; three patients (6.6%) died from liver cir-
rhosis, not explained by alcoholism. This liver damage was not
retrieved in other studies, but none of them, to our knowledge,
reported LFTs or liver imaging results.8,13,15,22,35 In the present
study, LFTs were within normal ranges, and no signs of hepatic
dysfunction were observed. One hypothesis about liver dysfunc-
tion reported in Dresler’s study is the presence of severe hepatic
steatosis or steatohepatitis, which has already been reported after
pancreatoduodenectomy in up to 33% of cases 6 months after
surgery.36 The risk factors of hepatic steatosis are still unknown
but a reduction in the post-operative body mass index greater
than 3 kg/m237 or use of old pancreatic enzyme formulations can
be hypothesized.
We also observed long-term altered bowel habits in 20% to
25% of our patients. Indeed, of the 25 patients we evaluated, 7
had night stools and 5 described diarrhoea stools as a limiting
factor in everyday life. Diarrhoea after TP results mainly from
exocrine insufficiency. After TP, a specific attention should be
given to the patients’ education with regards to exocrine insuffi-
ciency and pancreatic enzymes (to adapt the number of pancre-
atic enzymes tablets/capsules, to open the capsules or take
granules if needed). Another explanation for the diarrhoea is
the risk of nervous damage around the superior mesenteric
artery (SMA).38 Indeed, dissection of the SMA during TP is more
extensive than during a pancreaticoduodenectomy, resulting in
impaired bowel control, as strongly suggested in previous studies
that compared a regional versus extended lymphadenectomy
during a pancreaticoduodenectomy.36,38
Only three previous studies have evaluated the long-term QoL
after TP.13,15,35 Tables 4 and 5 summarize the results of these
studies and of the present one. Although not fully comparable,
these data showed similar scores for global health status (61 to
64%). Most impaired items after TP were symptoms scales, with
a decrease of quality of life focusing mainly on fatigue, pain and
diarrhoea as in Casadei’s study.35 Main differences between our
patients and reference patients concern eating and transit-related
items like diarrhoea, vomiting and loss of appetite. We herein
reported better QoL scores with the QLQ-PAN26 questionnaire
than Billings et al.15 regarding body image, eating restrictions,
pain and health care satisfaction. This decrease in QoL seems an
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unavoidable consequence of TP and should be explained pre-
operatively to the patient for more objective information. The
relatively low score of health care satisfaction should encourage
us to reinforce the delivered information before and after
surgery.
In conclusion, morbidity and mortality after TP are acceptable,
although diabetes- and TP-related mortality still occurs. Indica-
tions for TP should be driven by histology, as misdiagnoses
can occur. Specific attention should be paid to gastric venous
drainage, highlighting the importance of pylorus preservation and
adequate venous reconstruction if necessary. Definitive PPI
administration is strongly recommended in order to prevent anas-
tomotic ulcer. Long-term assessment shows that exocrine insuffi-
ciency impacts on everyday life in 20% of patients, but nutrition
issues after TP are now better managed. TP-induced diabetes
remains difficult to balance with frequent hypoglycaemias and
hospital readmissions, underlying the importance of diabetic edu-
cation after TP.
Table 2 Morbidity, mortality and survival after an elective a total pancreatectomy (TP) – main published series
Author Period
of time
Aetiologies Mortality
rate (%)
Morbidity
rate (%)
Diabetes Survival rates
Total Ductal
carcinoma
Invasive
IPMN
Non-
invasive
IPMN
Chronic
Pancreatitis
Endocrine
tumor
Renal
cancer
metastases
Other
malignant
Other
benign
Casadei
et al.35
2006–
2009
20 7 7 1 1 2 2 5% 25%, of which:
-hemorrhage=3
-biliary leakage=1
- No death
related to
diabetes
- 23%
readmissions
for glycemic
control
- Ductal
carcinoma:
3-y: 25%
- Others:
3-y: 90%; 5-y:
70%
Muller
et al.13
2001–
2006
124 67 10 8 11 10 8 6 4 4.8% 24% surgical
14.5% medical
- No death
related to
diabetes
- 8.3%
readmissions
for diabetes
control
- Malignant
disease:
3-y: 37%a
- Benign disease:
3-y: 88%a
Billings
et al.15
1985–
2002
99 33 17 9 20 20 5% 32% 3 deaths
owing to
hypoglycemia
- Malignant
disease:
5-y: 34%b
- Benign disease:
5y: 84%b
Schmidt
et al.21
1992–
2006
33 33 (all R0) 6.1% 48% – 3-y: 34%
5-y: 14%
Crippa
et al.8
1996–
2008
65 19 18 13 1 6 6 1 1 0 38.5%, of which:
-hemorrhage =3
-biliary leakage=1
No death
owing to
hypoglycemia
- All patients:
5-y: 71%
- Ductal
carcinoma:
3-y: 38%; 5-y:
0%
- Invasive IPMN:
3-y: 56%; 5-y:
45%
Reddy
et al.22
1970–
2007
100 100 8% ª68% – 3-y: 27%
5-y: 19%
Stauffer
et al.26
2002–
2008
47 10 10 21 2 1 1 1 1 2% 37% 23/46 living
patients were
readmitted
after discharge
3-y survival:
- All patients:
65%
- Ductal
carcinoma: 34%:
- Invasive IPMN:
49%
- Non-invasive
IPMN: 95%
Present
study
1993–
2010
56 4 28 11 1 6 2 1 3 3.6% 45% -1 death
owing to
hypoglycemia
-1 death
owing to
ketoacidosis
- All patients:
3-y = 62%, 5-y =
55%
- Invasive IPMN:
3-y = 40%, 5-y =
22%
- Non-invasive
IPMN:
3- and 5-y =
90%
aIncluding other patients with salvage TP.
bExcept patients who died in the postoperative period.
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Table 3 Endocrine and exocrine functions in the long-term after a a total pancreatectomy (TP) – Main published
Authors Period of
time
N = Median insulin
units/d
Median hypo-
glycaemia events
HbA1c Median pancreatic
lipase/d
Weight loss
% of patients
Nb of kg
Digestive symptoms
Crippa S et al.8 1996–2008 45 32 [18–52] 2 [0–5] per week 56% between 7 and 9
11% above 9%
80 000 units
[30 000–160 000]
45%
5 kg [1–18]
Abdominal pain 22%
Diarrhoea 13%
Muller et al.13 2001–2006 67 6.7% in benign disease
7.5% in malignant disease
41%
13.5 kg [6–30]
Diarrhoea 41%
Moderate to severe
abdominal pain 15%
Billings et al.15 1985–2002 27 32 [2–66] 7.4% (5.0–11.3] 14 capsulesa [0–36] 70%
12 kg [2–31]
Casadei et al.35 2006–2009 13 25 [20–52] 4 [1–10] hypo +
hyperglycemias
per week
8% [5.2–10.3] 8 capsulesa
[6–11]
85%
15 kg [1–32]
Present study 1993–2010 25 16 [7–48] of long-acting
insulin
21 [7–70] of rapid-acting
insulin
10 times [1–36]
per month
7.8 [6.3–10.3]
9 patients >8%
150 000 units
[75 000–450 000]
60%
9 kg [2–14]
2 [1–5] stools/day
28% with night stools
aNumber of pancreatic enzyme units not specified.
Table 4 Long-term assessment of quality-of-life with standardized questionnaires QLQ-C30 – Review of the Literature
Scales Casadei35
13 patients
Median [range]
Muller13
46 patients
Mean  standard
deviation
Present study
25 patients
Mean  standard
deviation
Median [range]
Global health 75 [0–83] 61  20 64  32
75 [17–100]
Function scales Physical functioning 80 [0–100] 78  23 84  21
93 [33–100]
Role functioning 83 [0–100] 67  29 75  33
83 [0–100]
Emotional functioning 75 [17–100] 70  22 76  28
92 [8–100]
Cognitive functioning 100 [0–100] 80  26 76  32
83 [0–100]
Social functioning 100 [0–100] 67  32 73  37
100 [0–100]
Symptom scales Fatigue 33 [0–89] 38  26 38  32
33 [0–100]
Nausea/vomiting 0 [0–67] 6  17 15  27
0 [0–100]
Pain 0 [0–83] 23  27 26  30
17 [0–100]
Dyspnoea 33 [0–100] 14  30 19  33
0 [0–100]
Insomnia 33 [0–100] 29  30 20  32
0 [0–100]
Loss of appetite 0 [0–100] 16  27 13  30
0 [0–100]
Constipation 0 [0–33] 8  21 9  18
0 [0–100]
Diarrhoea 33 [0–67] 28  32 25  32
33 [1–100]
Financial difficulties 0 20  27 16  29
0 [0–100]
A higher score represents better QoL for global health and functional scales and worse QoL for symptoms scales.
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